Replies to post #306313 on Innovation Pharmaceuticals Inc (IPIX)

[To infinity and beyond!]

What this whole discussion tells us is how little info Leo has bothered to divulge- next to nothing. And so there are questions that are really incredibly important that are unanswered.

Why? Because he cannot say? Because he wants the data to look better than they are?

That is what worries me given the BOM subsets and the pathetic P2b data presentation.

I am trying to get on board the B for c train.
It would be nice if the company bothered to help people get on board.

OK they announce they are making B for IV administration- but remember the B OM manufacturing contract? Signed before they ever got a pharma deal- pathetic

[KMBJN]

I think your understanding is very good, and I'm not one to question your motives, as I know you just want to understand better. We all do.

I'm not an expert, but my understanding is that they have cells growing in a dish, and then they add things to it. For pre-treatment, they add the "treatment" brilacidin to the dish before they add in the virus to infect the cells. They likewise add in the control (water or DSMO carrier), and compare what happens. If at the end of experiment control has 100 viral particles, then 97% reduction from pre-treatment with brilacidin means it only has 3 particles.

Same with post-treatment. They add in the virus to cells first, then 1 or however many hours later add in the treatment brilacidin or control, and compare how many viral particles at some period of time afterwards.

It's possible for pre-treatment they add in the brilacidin or control to virus solution before adding to cells. I don't know, but would seem unusual to me. The pre-print paper when it comes out will describe all the details.